title: Streptozotocin-induced hyperglycemia is decreased by nitric oxide inhibition.
abstract: 1. Diabetes mellitus type I was induced in 3-month old male C57 BL/KS-mdb mice (N = 24) by ip injection of streptozotocin (STZ, 45 mg/kg body weight) for 5 days. 2. To determine the possible protective effects of nitric oxide inhibition against hyperglycemia, the STZ-diabetic rats received two doses of NG-nitro-L-arginine- methyl ester (L-NAME) (10 mg/kg body weight and 10 mg/mouse) dissolved in PBS for 45 consecutive days. Another group of STZ-treated rats was similarly treated with L-arginine (5 mg/mouse). 3. Blood glucose levels were 118 +/- 37 mg/dl after 8 days of L-NAME administration (10 mg/kg body weight, N = 12) and 186 +/- 22 mg/dl (N = 12) after 5 days of L-NAME administration at the 5 mg/mouse dose. Treatment with L-arginine (5 mg/mouse, N = 12) caused a significant increase in blood glucose level to 151 +/- 17.5 mg/dl, showing the relevance of nitric oxide formation in this type of diabetes. 4. In STZ-diabetic mice treated with L-NAME (N = 12), diuresis was reduced by approximately 58% compared to STZ animals, whereas in L-arginine-treated animals (N = 12) diuresis returned to STZ levels. Urinary protein excretion, which was significantly affected by STZ (123% compared to control) was significantly reduced by 66% after treatment with L-NAME for 45 days, whereas treatment with L-arginine caused a return to STZ values. 5. Urinary kallikrein excretion, which was reduced by 80% in STZ mice compared to control, returned to control levels after L-NAME treatment. 6. The present results suggest a relationship between nitric oxide levels and the reduction of diabetic state and improved renal function by L-NAME.
authors.affiliation: PROSIVAD-CONICET, Facultad de Farmacia y Bioquímica, Cátedra de Fisiologia, Universidad de Buenos Aires, Argentina.
authors.forename: O L
authors.initials: OL
authors.lastname: Catanzaro
authors.forename: M G
authors.initials: MG
authors.lastname: Marina-Prendes
authors.forename: S I
authors.initials: SI
authors.lastname: Hope
authors.forename: A
authors.initials: A
authors.lastname: Zuccollo
authors.forename: A
authors.initials: A
authors.lastname: Dominguez
mesh_terms: D000818:Animals; D001120:Arginine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D001786:Blood Glucose / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D004231:Diuresis / Q000187:drug effects; D006943:Hyperglycemia / Q000139:chemically induced / Q000378:metabolism*; D007610:Kallikreins / Q000652:urine; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009569:Nitric Oxide / Q000037:antagonists & inhibitors* / Q000378:metabolism; D019335:Nitroarginine; D011507:Proteinuria / Q000378:metabolism; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D019335:Nitroarginine; D009569:Nitric Oxide; D001120:Arginine; D007610:Kallikreins